comparemela.com
Home
Live Updates
FDA Grants Priority Review to sBLA of Epcoritamab in Relapse
FDA Grants Priority Review to sBLA of Epcoritamab in Relapse
FDA Grants Priority Review to sBLA of Epcoritamab in Relapsed/Refractory Follicular Lymphoma
The FDA has granted priority review to the sBLA of epcoritamab for relapsed/refractory follicular lymphoma.
Related Keywords
,
Epcoritamab Bysp Epkinly ,
Fda ,
Follicular Lymphoma ,
2023 Ash Annual Meeting ,
Phase 1 2 Epcore Nhl Trial Nct03625037 ,
Jan Van De Winkel ,
Phd ,